Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected cisgender women from contracting HIV in a large Phase 3 trial.
In the study, none of the 2,134 women who received lenacapavir contracted HIV. By comparison, 16 of the 1,068 women who received the long-running daily pill Truvada contracted HIV. And 39 out of 2,136 women who received a newer daily pill called Descovy developed HIV.
“To have no infections in over 2,000 women. … I mean that’s a remarkable result,” said Joe Eron, principal investigator at the HIV/AIDS Clinical Research Unit at University of North Carolina-Chapel Hill.
Click this link for the original source of this article.
Author: Jason Mast
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.